ACS Chemical Neuroscience-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2024-08-03 朴减减来自浙江省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：药理;神经
经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。

1 0

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2023-08-28 ms6000002054670522 来自山东省

现在审稿要多久呀，快一个月了还是under review

93 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2022-02-09 ms5000001426662793

审稿速度:6.0 | 投稿命中率:25.0
经验分享：现在超慢，返修2次了

77 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2022-03-16 兵临城下house

有人知道这个杂志外审后的拒稿率大概是多少吗？

73 0

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2022-03-02 ms5000001426662793

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：药物化学
经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！

78 0

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2021-12-29 衣谷

评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？

79 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2021-12-27 MS54455111222

回复评审的意见和期刊编辑的意见有什么不同？

101 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2018-06-28 sumlower

审稿速度:1.0 | 投稿命中率:50.0
经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力

306 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2020-04-03 lekai726

审稿速度:2.0 | 投稿命中率:25.0
经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。

180 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2218253, encodeId=baca2218253bd, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：药理;神经 经验分享：这个杂志在国内比较小众，没太听过再加上发文量比较少所以不是太有名。但是编辑效率真的太高了。从投稿到接收才1个半月。6月17日投稿，7月22日返修，7月28日返回去，8月1日接收。而且还是非OA。真的点赞了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc828119412, createdName=朴减减, createdTime=Sat Aug 03 09:44:16 CST 2024, time=2024-08-03, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2154919, encodeId=c2ed21549196e, content=现在审稿要多久呀，快一个月了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67108233485, createdName=ms6000002054670522, createdTime=Mon Aug 28 10:40:16 CST 2023, time=2023-08-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1191517, encodeId=7189119151e0a, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：现在超慢，返修2次了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Feb 09 20:42:04 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203120, encodeId=e1e31203120c2, content=有人知道这个杂志外审后的拒稿率大概是多少吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10a05503477, createdName=兵临城下house, createdTime=Wed Mar 16 15:38:42 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198584, encodeId=974911985844f, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：药物化学 经验分享：美国化学会的子刊！影响因子虽不高，但文章质量很不错，之前属于药物化学一区！普遍高于一般的药物化学杂志！大约与EJMC相当！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5a35553126, createdName=ms5000001426662793, createdTime=Wed Mar 02 08:32:04 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103530, encodeId=7af31103530a5, content=评审要求我补充实验，可我的样品已经用完了/实验已经结束了，直接说我样本用完了会被拒稿么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103529, encodeId=64ae1103529d8, content=回复评审的意见和期刊编辑的意见有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558580, encodeId=3adc55858055, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：很好的杂志，稿件处理速度很快，一审大概一月，给了小修，审稿人意见比较专业，但没有刁钻的问题，花了10天左右小修上传后一天就接收了，从投稿到接收差不多一个半月，非常给力, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=306, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Thu Jun 28 16:27:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588092, encodeId=f90d5880922d, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：ACS旗下好多高分杂志。这本杂志比较讲创新吧，药物化学，新药物的应用都可以投，如果是机制的研究做的全一些比较好。三个审稿人，每个人都提了不少意见，一条一条认真修改，编辑人还挺好的，但是比较严格，一审给我拒了，但给了我重投的机会，保持在四分上下，今年预计4.5分，按稿件量来看，大概四分之一到三分之一的接收率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b3652595, createdName=lekai726, createdTime=Fri Apr 03 00:00:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563084, encodeId=95ff563084b5, content=没有版面费瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, beContent=瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=243, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06ef1724159, createdName=sumlower, createdTime=Sun Nov 11 00:00:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]

2018-11-11 sumlower

没有版面费瑞琼 2018-10-29 00:00:00 发表:
恭喜！要交版面费吗？

瑞琼 2018-10-29 00:00:00 发表: 恭喜！要交版面费吗？

243 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务